Organisation paid for research Program year 2024 Source: CMS Open Payments

Lycoming Internal Medicine

Neither a doctor nor a teaching hospital

Research payments

$83,782

76 payments

Through program year 2024, Lycoming Internal Medicine is reported as receiving $83,782 in research payments, across 76 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$575	2
2021	Research	$250	1
2020	Research	$34,122	17
2019	Research	$48,835	56

Breakdown

Who paid Research payments · program years 2019–2024

Bayer HealthCare Pharmaceuticals Inc. $44,965 17 payments
GlaxoSmithKline, LLC. $16,474 3 payments
Novo Nordisk AS $14,820 40 payments
AstraZeneca Pharmaceuticals LP $5,171 4 payments
Boehringer Ingelheim International GmbH $2,352 12 payments

Studies the money was for Research payments · program years 2019–2024

BAY94-8862 ph 3 conventional in diabetic nephropathy $44,965 17 payments
Nn9535-4321 $14,820 40 payments
A Long Term, Randomised, Double Blind, Placebo-Controlled Study to Det $12,974 2 payments
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease $5,171 4 payments
A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou $3,500 1 payment
Empagliflozin and heart failure (HFpEF) $2,352 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.